BCL2L11 and cancer: The EGFR-FOXO6-SOX2 signaling pathway regulating expression ofthe BIM and BMF apoptotic factors thus identifies a feedback loop that may attenuatethe effectiveness of anti-EGFR therapy in cancer and contribute toward the ultimatedevelopment of drug resistance (Figure 9).